 Connection
David Fox to Molecular Targeted Therapy
This is a "connection" page, showing publications David Fox has written about Molecular Targeted Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.326 |
|
|
|
-
Fechtner S, Fox DA, Ahmed S. Transforming growth factor ß activated kinase 1: a potential therapeutic target for rheumatic diseases. Rheumatology (Oxford). 2017 07 01; 56(7):1060-1068.
Score: 0.104
-
Baugh L, Phan I, Begley DW, Clifton MC, Armour B, Dranow DM, Taylor BM, Muruthi MM, Abendroth J, Fairman JW, Fox D, Dieterich SH, Staker BL, Gardberg AS, Choi R, Hewitt SN, Napuli AJ, Myers J, Barrett LK, Zhang Y, Ferrell M, Mundt E, Thompkins K, Tran N, Lyons-Abbott S, Abramov A, Sekar A, Serbzhinskiy D, Lorimer D, Buchko GW, Stacy R, Stewart LJ, Edwards TE, Van Voorhis WC, Myler PJ. Increasing the structural coverage of tuberculosis drug targets. Tuberculosis (Edinb). 2015 Mar; 95(2):142-8.
Score: 0.087
-
Cottier KE, Fogle EM, Fox DA, Ahmed S. Noxa in rheumatic diseases: present understanding and future impact. Rheumatology (Oxford). 2014 Sep; 53(9):1539-46.
Score: 0.081
-
Zhang L, Li Y, Qiu W, Bell BA, Dvorina N, Baldwin WM, Singer N, Kern T, Caspi RR, Fox DA, Lin F. Targeting CD6 for the treatment of experimental autoimmune uveitis. J Autoimmun. 2018 06; 90:84-93.
Score: 0.027
-
Asif Amin M, Fox DA, Ruth JH. Synovial cellular and molecular markers in rheumatoid arthritis. Semin Immunopathol. 2017 06; 39(4):385-393.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|